Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.

Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2013 Feb 1;119(3):665-71. doi: 10.1002/cncr.27783. Epub 2012 Sep 5. Review.

2.

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.

Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.

Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.

PMID:
18443961
3.

Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.

Schlemmer M, Wendtner CM, Falk M, Abdel-Rahman S, Licht T, Baumert J, Straka C, Hentrich M, Salat C, Hiddemann W, Issels RD.

Oncology. 2006;71(1-2):32-9. Epub 2007 Mar 5.

PMID:
17344669
4.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
5.

DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.

Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH.

Ann Hematol. 2013 Aug;92(8):1041-8. doi: 10.1007/s00277-013-1738-9. Epub 2013 Mar 27.

PMID:
23532626
6.

A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.

Takahashi M, Yoshizawa H, Tanaka H, Tanaka J, Kagamu H, Ito K, Shimbo T, Chou D, Wakabayashi M, Suzuki E, Sakai K, Arakawa M, Gejyo F.

Bone Marrow Transplant. 2000 Jan;25(1):5-11.

7.

High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

Kushner BH, Kramer K, Modak S, Cheung NK.

Pediatr Blood Cancer. 2011 Mar;56(3):403-8. doi: 10.1002/pbc.22855.

PMID:
21049517
8.

Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.

Goldman SC, Bracho F, Davenport V, Slack R, Areman E, Shen V, Lenarsky C, Weinthal J, Hughes R, Cairo MS.

J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):300-5.

PMID:
11464987
9.
10.

[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].

Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY.

Ai Zheng. 2006 Dec;25(12):1550-2. Chinese.

PMID:
17166384
11.
12.
13.

High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.

Elias AD, Ayash LJ, Wheeler C, Schwartz G, Tepler I, McCauley M, Mazanet R, Schnipper L, Frei E 3rd, Antman KH.

Semin Oncol. 1994 Oct;21(5 Suppl 12):83-5.

PMID:
7992072
14.

Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.

Broun ER, Nichols CR, Gize G, Cornetta K, Hromas RA, Schacht B, Einhorn LH.

Cancer. 1997 Apr 15;79(8):1605-10.

PMID:
9118046
15.

A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ, et al.

Semin Oncol. 1995 Aug;22(4 Suppl 9):70-4.

PMID:
7544029
16.

Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.

Chang AY, Boros L, Garrow GC, Asbury RF, Hui L.

Semin Oncol. 1996 Jun;23(3 Suppl 6):74-7.

PMID:
8677454
18.

A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.

Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G; Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation.

J Natl Cancer Inst. 2008 Apr 16;100(8):533-41. doi: 10.1093/jnci/djn088. Epub 2008 Apr 8.

PMID:
18398095
19.

High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.

Fields KK, Elfenbein GJ, Perkins JB, Janssen WE, Ballester OF, Hiemenz JW, Zorsky PE, Kronish LE, Foody MC.

Semin Oncol. 1994 Oct;21(5 Suppl 12):86-92.

PMID:
7527592
20.

Supplemental Content

Support Center